Fox Chase Cancer Center | Strategic Alliance Partners

From barely escaping a life under communism in a Russia-occupied Latvia to overcoming a family health crisis, Robert F. Ozols, MD, PhD, knows a thing or two about beating the odds.

Mitchell Fane, PhD, has received a grant to investigate the role of aging in immune-regulated reactivation from metastatic melanoma.

Kara Stromberg, MS, RD, LDN, CDCES, was recognized by the Pennsylvania Academy of Nutrition and Dietetics as a Keystone Award winner.

Fox Chase Cancer Center researchers showed that in men who underwent prostate cancer surgery, urinary sphincter function improved with adjuvant radiation.

Fox Chase Researchers Examine Alternative Methods of Specialized Imaging Scans for Kidney Masses

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.

Alexander Kutikov, MD, FACS, discusses treatment options for patients with urothelial cancer requiring cystectomy.

Fox Chase Cancer Center researchers showed that estrogen is metabolized in lungs, contributing to the development of lung cancer in never smokers.

Fox Chase Cancer Center is proud to welcome patients to its newly opened office, which is located at 502 Centennial Boulevard in Voorhees, New Jersey.

Fox Chase Cancer Center has been recognized by the QOPI Certification Program LLC as successfully completing a 3-year recertification for outpatient hematology-oncology practices that meet nationally recognized standards for quality cancer care.

The journal European Urology has named Fox Chase Cancer Center urologic oncologist Andres F. Correa, MD, its March 2024 Reviewer of the Month.

Sanjay S. Reddy, MD, FACS, of Fox Chase Cancer Center was recently chosen as a participant in the Society of Surgical Oncology’s inaugural Career Catalyst Mentorship Program.

Anthony Villano, MD, and Joceline Vu, MD, were recently elected members of the Education Committee of the Association for Academic Surgery.

Elizabeth Plimack, MD, MS, FASCO, recaps the discussion with key takeaways on recent updates in bladder cancer.

Efrat Dotan, MD, discusses a retrospective study aiming to understand the needs of geriatric patients with gastroesophageal cancer.

Experts on bladder cancer discuss exciting new agents and treatment strategies and where they can potentially fit into urothelial cancer treatment paradigms.

Focusing on metastatic urothelial carcinoma, the panel discusses the role of chemotherapy and outlines treatment sequencing approaches.

Evan Y. Yu, MD, provides insights on treatment approaches for patients with metastatic urothelial carcinoma in the second line and beyond.

The expert panel discusses how treatment strategies change based on cisplatin eligibility and the role of maintenance therapy in metastatic urothelial carcinoma.

Andrea Porpiglia, MD, MSc, FACS, and Sanjay Reddy, MD, FACS describe what makes the Complex General Surgical Oncology Fellowship at Fox Chase unique.

GU medical oncologists offer their impressions of recent updates in the metastatic urothelial carcinoma space, focusing on CheckMate 901 and EV-302.

Neeraj Agarwal, MD, FASCO, provides a comprehensive overview of recent data in metastatic urothelial carcinoma, highlighting the CheckMate 901 and EV-302 studies.

It is often said that one person can make a difference, but it is also evident that when we band together, we can achieve greatness.

Experts on muscle-invasive bladder cancer respond to recent data in adjuvant therapy that were presented at ASCO GU 2024.

Following an overview of the evolving adjuvant therapy space, Matthew Milowsky, MD, FASCO, reviews recent updates from ASCO GU 2024 in muscle-invasive bladder cancer.

Focusing on neoadjuvant therapy, the expert panel discusses ongoing clinical research in muscle-invasive bladder cancer and the potential role of novel strategies in the treatment space.

A panel of experts on bladder cancer introduce themselves and give an overview of the neoadjuvant therapy landscape for patients with muscle-invasive bladder cancer.

Efrat Dotan, MD, discusses routine provider assessment vs the utility of geriatric assessment in geriatric patients with gastroesophageal disease.

Efrat Dotan, MD, discusses the use of geriatric function assessments in elderly patients with gastroesophageal cancer.

Billy Truong discusses the rationale for investigating the functions of ERK2 substrate binding modalities in patients with myeloproliferative neoplasms.